Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Hemophilia Drugs market report explains the definition, types, applications, major countries, and major players of the Hemophilia Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Alnylam Pharmaceuticals
Swedish Orphan Biovitrum
Sangamo Biosciences
Baxalta
Pfizer
BioMarin
Grifols
Catalyst Biosciences
Spark Therapeutics
F Hoffmann-La Roche
CSL Behring
Dimension Therapeutics
Bayer
Octapharma
By Type:
Hemophilia A
Inhibitors
Hemophilia B
Von Willebrand Disease
By End-User:
Recombinant Therapies
Plasma-Derived Therapies
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Hemophilia Drugs Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Hemophilia Drugs Outlook to 2028- Original Forecasts
-
2.2 Hemophilia Drugs Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Hemophilia Drugs Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Hemophilia Drugs Market- Recent Developments
-
6.1 Hemophilia Drugs Market News and Developments
-
6.2 Hemophilia Drugs Market Deals Landscape
7 Hemophilia Drugs Raw Materials and Cost Structure Analysis
-
7.1 Hemophilia Drugs Key Raw Materials
-
7.2 Hemophilia Drugs Price Trend of Key Raw Materials
-
7.3 Hemophilia Drugs Key Suppliers of Raw Materials
-
7.4 Hemophilia Drugs Market Concentration Rate of Raw Materials
-
7.5 Hemophilia Drugs Cost Structure Analysis
-
7.5.1 Hemophilia Drugs Raw Materials Analysis
-
7.5.2 Hemophilia Drugs Labor Cost Analysis
-
7.5.3 Hemophilia Drugs Manufacturing Expenses Analysis
8 Global Hemophilia Drugs Import and Export Analysis (Top 10 Countries)
-
8.1 Global Hemophilia Drugs Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Hemophilia Drugs Export by Region (Top 10 Countries) (2017-2028)
9 Global Hemophilia Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Hemophilia Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Hemophilia A Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Hemophilia B Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Von Willebrand Disease Consumption and Growth Rate (2017-2022)
-
9.2 Global Hemophilia Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Recombinant Therapies Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Plasma-Derived Therapies Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Hemophilia Drugs Market Analysis and Outlook till 2022
-
10.1 Global Hemophilia Drugs Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Hemophilia Drugs Consumption (2017-2022)
-
10.2.2 Canada Hemophilia Drugs Consumption (2017-2022)
-
10.2.3 Mexico Hemophilia Drugs Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Hemophilia Drugs Consumption (2017-2022)
-
10.3.2 UK Hemophilia Drugs Consumption (2017-2022)
-
10.3.3 Spain Hemophilia Drugs Consumption (2017-2022)
-
10.3.4 Belgium Hemophilia Drugs Consumption (2017-2022)
-
10.3.5 France Hemophilia Drugs Consumption (2017-2022)
-
10.3.6 Italy Hemophilia Drugs Consumption (2017-2022)
-
10.3.7 Denmark Hemophilia Drugs Consumption (2017-2022)
-
10.3.8 Finland Hemophilia Drugs Consumption (2017-2022)
-
10.3.9 Norway Hemophilia Drugs Consumption (2017-2022)
-
10.3.10 Sweden Hemophilia Drugs Consumption (2017-2022)
-
10.3.11 Poland Hemophilia Drugs Consumption (2017-2022)
-
10.3.12 Russia Hemophilia Drugs Consumption (2017-2022)
-
10.3.13 Turkey Hemophilia Drugs Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Hemophilia Drugs Consumption (2017-2022)
-
10.4.2 Japan Hemophilia Drugs Consumption (2017-2022)
-
10.4.3 India Hemophilia Drugs Consumption (2017-2022)
-
10.4.4 South Korea Hemophilia Drugs Consumption (2017-2022)
-
10.4.5 Pakistan Hemophilia Drugs Consumption (2017-2022)
-
10.4.6 Bangladesh Hemophilia Drugs Consumption (2017-2022)
-
10.4.7 Indonesia Hemophilia Drugs Consumption (2017-2022)
-
10.4.8 Thailand Hemophilia Drugs Consumption (2017-2022)
-
10.4.9 Singapore Hemophilia Drugs Consumption (2017-2022)
-
10.4.10 Malaysia Hemophilia Drugs Consumption (2017-2022)
-
10.4.11 Philippines Hemophilia Drugs Consumption (2017-2022)
-
10.4.12 Vietnam Hemophilia Drugs Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Hemophilia Drugs Consumption (2017-2022)
-
10.5.2 Colombia Hemophilia Drugs Consumption (2017-2022)
-
10.5.3 Chile Hemophilia Drugs Consumption (2017-2022)
-
10.5.4 Argentina Hemophilia Drugs Consumption (2017-2022)
-
10.5.5 Venezuela Hemophilia Drugs Consumption (2017-2022)
-
10.5.6 Peru Hemophilia Drugs Consumption (2017-2022)
-
10.5.7 Puerto Rico Hemophilia Drugs Consumption (2017-2022)
-
10.5.8 Ecuador Hemophilia Drugs Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Hemophilia Drugs Consumption (2017-2022)
-
10.6.2 Kuwait Hemophilia Drugs Consumption (2017-2022)
-
10.6.3 Oman Hemophilia Drugs Consumption (2017-2022)
-
10.6.4 Qatar Hemophilia Drugs Consumption (2017-2022)
-
10.6.5 Saudi Arabia Hemophilia Drugs Consumption (2017-2022)
-
10.6.6 United Arab Emirates Hemophilia Drugs Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Hemophilia Drugs Consumption (2017-2022)
-
10.7.2 South Africa Hemophilia Drugs Consumption (2017-2022)
-
10.7.3 Egypt Hemophilia Drugs Consumption (2017-2022)
-
10.7.4 Algeria Hemophilia Drugs Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Hemophilia Drugs Consumption (2017-2022)
-
10.8.2 New Zealand Hemophilia Drugs Consumption (2017-2022)
11 Global Hemophilia Drugs Competitive Analysis
-
11.1 Alnylam Pharmaceuticals
-
11.1.1 Alnylam Pharmaceuticals Company Details
-
11.1.2 Alnylam Pharmaceuticals Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Alnylam Pharmaceuticals Hemophilia Drugs Main Business and Markets Served
-
11.1.4 Alnylam Pharmaceuticals Hemophilia Drugs Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Swedish Orphan Biovitrum
-
11.2.1 Swedish Orphan Biovitrum Company Details
-
11.2.2 Swedish Orphan Biovitrum Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Swedish Orphan Biovitrum Hemophilia Drugs Main Business and Markets Served
-
11.2.4 Swedish Orphan Biovitrum Hemophilia Drugs Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Sangamo Biosciences
-
11.3.1 Sangamo Biosciences Company Details
-
11.3.2 Sangamo Biosciences Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Sangamo Biosciences Hemophilia Drugs Main Business and Markets Served
-
11.3.4 Sangamo Biosciences Hemophilia Drugs Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Baxalta
-
11.4.1 Baxalta Company Details
-
11.4.2 Baxalta Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Baxalta Hemophilia Drugs Main Business and Markets Served
-
11.4.4 Baxalta Hemophilia Drugs Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Pfizer
-
11.5.1 Pfizer Company Details
-
11.5.2 Pfizer Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Pfizer Hemophilia Drugs Main Business and Markets Served
-
11.5.4 Pfizer Hemophilia Drugs Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 BioMarin
-
11.6.1 BioMarin Company Details
-
11.6.2 BioMarin Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 BioMarin Hemophilia Drugs Main Business and Markets Served
-
11.6.4 BioMarin Hemophilia Drugs Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Grifols
-
11.7.1 Grifols Company Details
-
11.7.2 Grifols Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Grifols Hemophilia Drugs Main Business and Markets Served
-
11.7.4 Grifols Hemophilia Drugs Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Catalyst Biosciences
-
11.8.1 Catalyst Biosciences Company Details
-
11.8.2 Catalyst Biosciences Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Catalyst Biosciences Hemophilia Drugs Main Business and Markets Served
-
11.8.4 Catalyst Biosciences Hemophilia Drugs Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Spark Therapeutics
-
11.9.1 Spark Therapeutics Company Details
-
11.9.2 Spark Therapeutics Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Spark Therapeutics Hemophilia Drugs Main Business and Markets Served
-
11.9.4 Spark Therapeutics Hemophilia Drugs Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 F Hoffmann-La Roche
-
11.10.1 F Hoffmann-La Roche Company Details
-
11.10.2 F Hoffmann-La Roche Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 F Hoffmann-La Roche Hemophilia Drugs Main Business and Markets Served
-
11.10.4 F Hoffmann-La Roche Hemophilia Drugs Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 CSL Behring
-
11.11.1 CSL Behring Company Details
-
11.11.2 CSL Behring Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 CSL Behring Hemophilia Drugs Main Business and Markets Served
-
11.11.4 CSL Behring Hemophilia Drugs Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Dimension Therapeutics
-
11.12.1 Dimension Therapeutics Company Details
-
11.12.2 Dimension Therapeutics Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Dimension Therapeutics Hemophilia Drugs Main Business and Markets Served
-
11.12.4 Dimension Therapeutics Hemophilia Drugs Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Bayer
-
11.13.1 Bayer Company Details
-
11.13.2 Bayer Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Bayer Hemophilia Drugs Main Business and Markets Served
-
11.13.4 Bayer Hemophilia Drugs Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Octapharma
-
11.14.1 Octapharma Company Details
-
11.14.2 Octapharma Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Octapharma Hemophilia Drugs Main Business and Markets Served
-
11.14.4 Octapharma Hemophilia Drugs Product Portfolio
-
11.14.5 Recent Research and Development Strategies
12 Global Hemophilia Drugs Market Outlook by Types and Applications to 2028
-
12.1 Global Hemophilia Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Hemophilia A Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Hemophilia B Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Von Willebrand Disease Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Hemophilia Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Recombinant Therapies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Plasma-Derived Therapies Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Hemophilia Drugs Market Analysis and Outlook to 2028
-
13.1 Global Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.2.2 Canada Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.2.3 Mexico Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3.2 UK Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3.3 Spain Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3.4 Belgium Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3.5 France Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3.6 Italy Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3.7 Denmark Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3.8 Finland Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3.9 Norway Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3.10 Sweden Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3.11 Poland Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3.12 Russia Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.3.13 Turkey Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.4.2 Japan Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.4.3 India Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.4.4 South Korea Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.4.8 Thailand Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.4.9 Singapore Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.4.11 Philippines Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.5.2 Colombia Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.5.3 Chile Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.5.4 Argentina Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.5.6 Peru Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.6.3 Oman Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.6.4 Qatar Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.7.2 South Africa Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.7.3 Egypt Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.7.4 Algeria Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Hemophilia Drugs Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Hemophilia Drugs Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Hemophilia Drugs
-
Figure of Hemophilia Drugs Picture
-
Table Global Hemophilia Drugs Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Hemophilia Drugs Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Hemophilia A Consumption and Growth Rate (2017-2022)
-
Figure Global Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Hemophilia B Consumption and Growth Rate (2017-2022)
-
Figure Global Von Willebrand Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Recombinant Therapies Consumption and Growth Rate (2017-2022)
-
Figure Global Plasma-Derived Therapies Consumption and Growth Rate (2017-2022)
-
Figure Global Hemophilia Drugs Consumption by Country (2017-2022)
-
Table North America Hemophilia Drugs Consumption by Country (2017-2022)
-
Figure United States Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Canada Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Mexico Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Hemophilia Drugs Consumption by Country (2017-2022)
-
Figure Germany Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure UK Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Spain Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Belgium Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure France Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Italy Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Denmark Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Finland Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Norway Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Sweden Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Poland Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Russia Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Turkey Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Table APAC Hemophilia Drugs Consumption by Country (2017-2022)
-
Figure China Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Thailand Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Singapore Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Philippines Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Table South America Hemophilia Drugs Consumption by Country (2017-2022)
-
Figure Brazil Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Colombia Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Chile Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Argentina Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Peru Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Table GCC Hemophilia Drugs Consumption by Country (2017-2022)
-
Figure Bahrain Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Oman Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Qatar Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Table Africa Hemophilia Drugs Consumption by Country (2017-2022)
-
Figure Nigeria Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Africa Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Egypt Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure Algeria Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Table Oceania Hemophilia Drugs Consumption by Country (2017-2022)
-
Figure Australia Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Hemophilia Drugs Consumption and Growth Rate (2017-2022)
-
Table Alnylam Pharmaceuticals Company Details
-
Table Alnylam Pharmaceuticals Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Alnylam Pharmaceuticals Hemophilia Drugs Main Business and Markets Served
-
Table Alnylam Pharmaceuticals Hemophilia Drugs Product Portfolio
-
Table Swedish Orphan Biovitrum Company Details
-
Table Swedish Orphan Biovitrum Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Swedish Orphan Biovitrum Hemophilia Drugs Main Business and Markets Served
-
Table Swedish Orphan Biovitrum Hemophilia Drugs Product Portfolio
-
Table Sangamo Biosciences Company Details
-
Table Sangamo Biosciences Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sangamo Biosciences Hemophilia Drugs Main Business and Markets Served
-
Table Sangamo Biosciences Hemophilia Drugs Product Portfolio
-
Table Baxalta Company Details
-
Table Baxalta Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Baxalta Hemophilia Drugs Main Business and Markets Served
-
Table Baxalta Hemophilia Drugs Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Hemophilia Drugs Main Business and Markets Served
-
Table Pfizer Hemophilia Drugs Product Portfolio
-
Table BioMarin Company Details
-
Table BioMarin Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table BioMarin Hemophilia Drugs Main Business and Markets Served
-
Table BioMarin Hemophilia Drugs Product Portfolio
-
Table Grifols Company Details
-
Table Grifols Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Grifols Hemophilia Drugs Main Business and Markets Served
-
Table Grifols Hemophilia Drugs Product Portfolio
-
Table Catalyst Biosciences Company Details
-
Table Catalyst Biosciences Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Catalyst Biosciences Hemophilia Drugs Main Business and Markets Served
-
Table Catalyst Biosciences Hemophilia Drugs Product Portfolio
-
Table Spark Therapeutics Company Details
-
Table Spark Therapeutics Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Spark Therapeutics Hemophilia Drugs Main Business and Markets Served
-
Table Spark Therapeutics Hemophilia Drugs Product Portfolio
-
Table F Hoffmann-La Roche Company Details
-
Table F Hoffmann-La Roche Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffmann-La Roche Hemophilia Drugs Main Business and Markets Served
-
Table F Hoffmann-La Roche Hemophilia Drugs Product Portfolio
-
Table CSL Behring Company Details
-
Table CSL Behring Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table CSL Behring Hemophilia Drugs Main Business and Markets Served
-
Table CSL Behring Hemophilia Drugs Product Portfolio
-
Table Dimension Therapeutics Company Details
-
Table Dimension Therapeutics Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Dimension Therapeutics Hemophilia Drugs Main Business and Markets Served
-
Table Dimension Therapeutics Hemophilia Drugs Product Portfolio
-
Table Bayer Company Details
-
Table Bayer Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer Hemophilia Drugs Main Business and Markets Served
-
Table Bayer Hemophilia Drugs Product Portfolio
-
Table Octapharma Company Details
-
Table Octapharma Hemophilia Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Octapharma Hemophilia Drugs Main Business and Markets Served
-
Table Octapharma Hemophilia Drugs Product Portfolio
-
Figure Global Hemophilia A Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hemophilia B Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Von Willebrand Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Recombinant Therapies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Plasma-Derived Therapies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hemophilia Drugs Consumption Forecast by Country (2022-2028)
-
Table North America Hemophilia Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Hemophilia Drugs Consumption Forecast by Country (2022-2028)
-
Figure Germany Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Hemophilia Drugs Consumption Forecast by Country (2022-2028)
-
Figure China Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Hemophilia Drugs Consumption Forecast by Country (2022-2028)
-
Figure Brazil Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Hemophilia Drugs Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Hemophilia Drugs Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Hemophilia Drugs Consumption Forecast by Country (2022-2028)
-
Figure Australia Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Hemophilia Drugs Consumption Forecast and Growth Rate (2022-2028)
-
